257 related articles for article (PubMed ID: 23651191)
41. Optimizing dendritic cell-based approaches for cancer immunotherapy.
Datta J; Terhune JH; Lowenfeld L; Cintolo JA; Xu S; Roses RE; Czerniecki BJ
Yale J Biol Med; 2014 Dec; 87(4):491-518. PubMed ID: 25506283
[TBL] [Abstract][Full Text] [Related]
42. Processing and presentation of antigens by dendritic cells: implications for vaccines.
Bhardwaj N
Trends Mol Med; 2001 Sep; 7(9):388-94. PubMed ID: 11530333
[TBL] [Abstract][Full Text] [Related]
43. Immune system versus tumor: shifting the balance in favor of DCs and effective immunity.
Kaufman HL; Disis ML
J Clin Invest; 2004 Mar; 113(5):664-7. PubMed ID: 14991063
[TBL] [Abstract][Full Text] [Related]
44. Role of CD4+ T lymphocytes in antitumor immunity.
Rajnavölgyi E; Lányi A
Adv Cancer Res; 2003; 87():195-249. PubMed ID: 12641277
[No Abstract] [Full Text] [Related]
45. Strategies to improve dendritic cell-based immunotherapy against cancer.
Song SY; Kim HS
Yonsei Med J; 2004 Jun; 45 Suppl():48-52. PubMed ID: 15250050
[TBL] [Abstract][Full Text] [Related]
46. Modulation of antitumor responses by dendritic cells.
Vieweg J; Jackson A
Springer Semin Immunopathol; 2005 Jan; 26(3):329-41. PubMed ID: 15609005
[TBL] [Abstract][Full Text] [Related]
47. Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.
Goyvaerts C; Breckpot K
J Immunol Res; 2015; 2015():785634. PubMed ID: 26583156
[TBL] [Abstract][Full Text] [Related]
48. Tolerogenic dendritic cells: key regulators of peripheral tolerance in health and disease.
Saei A; Hadjati J
Int Arch Allergy Immunol; 2013; 161(4):293-303. PubMed ID: 23689518
[TBL] [Abstract][Full Text] [Related]
49. Dendritic cell-based therapy: a review focusing on antigenic selection.
Syme RM; Bryan TL; Glück S
J Hematother Stem Cell Res; 2001 Oct; 10(5):601-8. PubMed ID: 11672506
[TBL] [Abstract][Full Text] [Related]
50. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells.
Yewdall AW; Drutman SB; Jinwala F; Bahjat KS; Bhardwaj N
PLoS One; 2010 Jun; 5(6):e11144. PubMed ID: 20585396
[TBL] [Abstract][Full Text] [Related]
51. Understanding dendritic cell immunotherapy in ovarian cancer.
Drakes ML; Stiff PJ
Expert Rev Anticancer Ther; 2016 Jun; 16(6):643-52. PubMed ID: 27078511
[TBL] [Abstract][Full Text] [Related]
52. Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.
Tsen SW; Paik AH; Hung CF; Wu TC
Expert Rev Vaccines; 2007 Apr; 6(2):227-39. PubMed ID: 17408372
[TBL] [Abstract][Full Text] [Related]
53. Hematologic neoplasms: Dendritic cells vaccines in motion.
Galati D; Zanotta S
Clin Immunol; 2017 Oct; 183():181-190. PubMed ID: 28870867
[TBL] [Abstract][Full Text] [Related]
54. Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.
Fecek RJ; Storkus WJ
Immunotherapy; 2016 Oct; 8(10):1205-18. PubMed ID: 27605069
[TBL] [Abstract][Full Text] [Related]
55. Dendritic cell based personalized immunotherapy based on cancer antigen research.
Kawakami Y; Fujita T; Kudo C; Sakurai T; Udagawa M; Yaguchi T; Hasegawa G; Hayashi E; Ueda Y; Iwata T; Wang Q; Okada S; Tsukamoto N; Matsuzaki Y; Sumimoto H
Front Biosci; 2008 Jan; 13():1952-8. PubMed ID: 17981682
[TBL] [Abstract][Full Text] [Related]
56. Immunotherapy exploiting the versatility of dendritic cells.
Kadowaki N
Ther Apher Dial; 2003 Jun; 7(3):312-7. PubMed ID: 12924606
[TBL] [Abstract][Full Text] [Related]
57. Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents.
Truxova I; Hensler M; Skapa P; Halaska MJ; Laco J; Ryska A; Spisek R; Fucikova J
Int Rev Cell Mol Biol; 2017; 330():115-156. PubMed ID: 28215530
[TBL] [Abstract][Full Text] [Related]
58. Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy.
Browning MJ
Hum Vaccin Immunother; 2013 Jul; 9(7):1545-8. PubMed ID: 23475129
[TBL] [Abstract][Full Text] [Related]
59. Role of Local Radiation Therapy in Cancer Immunotherapy.
Demaria S; Golden EB; Formenti SC
JAMA Oncol; 2015 Dec; 1(9):1325-32. PubMed ID: 26270858
[TBL] [Abstract][Full Text] [Related]
60. Engineering dendritic cell vaccines to improve cancer immunotherapy.
Perez CR; De Palma M
Nat Commun; 2019 Nov; 10(1):5408. PubMed ID: 31776331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
